Anti-inflammatory Therapy with Canakinumab for Atherosclerotic Disease - The New England Journal of Medicine - 2017

Brief Summary:

Anti-inflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months was associated with 0.6% absolute reduction in cardiovascular events, driven by a comparable reduction in nonfatal MI. Use of canakinumab was also associated with 0.13% absolute increase in fatal infection.